Form 4 for RGNX REGENXBIO Inc.
Accepted 2022-08-31 00:00:00 ET · period of report 2022-08-30 · accession 0001562180-22-006398 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-08-31 | 2022-08-30 | RGNX | Vasista Vittal | CFO | S - Sale | $30.24 | -2,400 | 135.2K | -2% | -$72.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-08-30 | S | D | 2,400 | $30.24 | 135,160 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $30.04 to $30.63. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |